Fore scores $75M Series D, tees up new leadership with ex-Elevation CEO Shawn Leland at the helm — for now
Fore Biotherapeutics has reeled in a $75 million Series D, and its CEO Matthew Ros is walking off the course for “other professional pursuits,” the Philadelphia drug developer said Wednesday morning.
Originally an Israeli diagnostics company known as Novellus, Fore made the transition to pharmaceuticals a few years ago, driven in part by its licensing of a Daiichi Sankyo BRAF inhibitor in 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.